AUP-16

About Aurealis Therapeutics

Aurealis Therapeutics is a private, clinical-stage biotech leveraging a proprietary 4-in-1 multi-target cell and gene therapy platform. Its lead program, AUP-16, has shown promising Phase 2 results in diabetic foot ulcers, tripling complete wound closure rates. The company is advancing this program while also developing an oncology candidate, AUP-55, and has recently secured CHF 8 million in funding to support its clinical pipeline.

Therapeutic Areas